Reversal of SARS-CoV2-Induced Hypoxia by Nebulized Sodium Ibuprofenate in a Compassionate Use Program

Autores
Salva, Oscar; Doreski, Pablo A.; Giler, Celia S.; Quinodoz, Dario C.; Guzmán, Lucia G.; Muñoz, Sonia Edith; Carrillo, Mariana Norma del Valle; Porta, Daniela Josefina; Ambasch, Germán; Coscia, Esteban; Tambini Diaz, Jorge L.; Bueno, Germán D.; Fandi, Jorge O.; Maldonado, Miriam A.; Peña Chiappero, Leandro E.; Fournier, Fernando; Pérez, Hernán A.; Quiroga, Mauro A.; Sala Mercado, Javier Agustin; Martínez Picco, Carlos; Beltrán, Marcelo Alejandro; Castillo Argañarás, Luis Fernando; Ríos, Nicolás Martínez; Kalayan, Galia I.; Beltramo, Dante Miguel; Garcia, Nestor Horacio
Año de publicación
2021
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Introduction: Sodium ibuprofenate in hypertonic saline (NaIHS) administered directly to the lungs by nebulization and inhalation has antibacterial and anti-inflammatory effects, with the potential to deliver these benefits to hypoxic patients. We describe a compassionate use program that offered this therapy to hospitalized COVID-19 patients. Methods: NaIHS (50 mg ibuprofen, tid) was provided in addition to standard of care (SOC) to hospitalized COVID-19 patients until oxygen saturation levels of > 94% were achieved on ambient air. Patients wore a containment hood to diminish aerosolization. Outcome data from participating patients treated at multiple hospitals in Argentina between April 4 and October 31, 2020, are summarized. Results were compared with a retrospective contemporaneous control (CC) group of hospitalized COVID-19 patients with SOC alone during the same time frame from a subset of participating hospitals from Córdoba and Buenos Aires. Results: The evolution of 383 patients treated with SOC + NaIHS [56 on mechanical ventilation (MV) at baseline] and 195 CC (21 on MV at baseline) are summarized. At baseline, NaIHS-treated patients had basal oxygen saturation of 90.7 ± 0.2% (74.3% were on supplemental oxygen at baseline) and a basal respiratory rate of 22.7 ± 0.3 breath/min. In the CC group, basal oxygen saturation was 92.6 ± 0.4% (52.1% were on oxygen supplementation at baseline) and respiratory rate was 19.3 ± 0.3 breath/min. Despite greater pulmonary compromise at baseline in the NaIHS-treated group, the length of treatment (LOT) was 9.1 ± 0.2 gs with an average length of stay (ALOS) of 11.5 ± 0.3 days, in comparison with an ALOS of 13.3 ± 0.9 days in the CC group. In patients on MV who received NaIHS, the ALOS was lower than in the CC group. In both NaIHS-treated groups, a rapid reversal of deterioration in oxygenation and NEWS2 scores was observed acutely after initiation of NaIHS therapy. No serious adverse events were considered related to ibuprofen therapy. Mortality was lower in both NaIHS groups compared with CC groups. Conclusions: Treatment of COVID-19 pneumonitis with inhalational nebulized NaIHS was associated with rapid improvement in hypoxia and vital signs, with no serious adverse events attributed to therapy. Nebulized NaIHS s worthy of further study in randomized, placebo-controlled trials (ClinicalTrials.gov: NCT04382768).
Fil: Salva, Oscar. Clínica Independencia; Argentina
Fil: Doreski, Pablo A.. Fundación Respirar; Argentina
Fil: Giler, Celia S.. Clínica Independencia; Argentina
Fil: Quinodoz, Dario C.. Sanatorio de la Cañada; Argentina
Fil: Guzmán, Lucia G.. Sanatorio de la Cañada; Argentina
Fil: Muñoz, Sonia Edith. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones en Ciencias de la Salud. Universidad Nacional de Córdoba. Instituto de Investigaciones en Ciencias de la Salud; Argentina
Fil: Carrillo, Mariana Norma del Valle. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones en Ciencias de la Salud. Universidad Nacional de Córdoba. Instituto de Investigaciones en Ciencias de la Salud; Argentina
Fil: Porta, Daniela Josefina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones en Ciencias de la Salud. Universidad Nacional de Córdoba. Instituto de Investigaciones en Ciencias de la Salud; Argentina
Fil: Ambasch, Germán. Sanatorio Privado Mayo; Argentina
Fil: Coscia, Esteban. Sanatorio Privado Mayo; Argentina
Fil: Tambini Diaz, Jorge L.. Sanatorio Privado Mayo; Argentina
Fil: Bueno, Germán D.. Sanatorio Privado Mayo; Argentina
Fil: Fandi, Jorge O.. Clínica Independencia; Argentina
Fil: Maldonado, Miriam A.. Sanatorio San Roque; Argentina
Fil: Peña Chiappero, Leandro E.. Sanatori San Roque; Argentina
Fil: Fournier, Fernando. Clínica Francesa; Argentina
Fil: Pérez, Hernán A.. Sanatorio Alive; Argentina. University of Maryland; Estados Unidos
Fil: Quiroga, Mauro A.. Instituto Modelo de Cardiología; Argentina
Fil: Sala Mercado, Javier Agustin. Instituto Modelo de Cardiología; Argentina
Fil: Martínez Picco, Carlos. Clínica del Sol; Argentina
Fil: Beltrán, Marcelo Alejandro. Hospital Dr. Alberto Duhau; Argentina
Fil: Castillo Argañarás, Luis Fernando. Hospital Dr. Alberto Duhau; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Ríos, Nicolás Martínez. Quimica Luar Srl; Argentina
Fil: Kalayan, Galia I.. Provincia de Córdoba. Ministerio de Ciencia y Técnica. Centro de Excelencia en Productos y Procesos de Córdoba; Argentina
Fil: Beltramo, Dante Miguel. Provincia de Córdoba. Ministerio de Ciencia y Técnica. Centro de Excelencia en Productos y Procesos de Córdoba; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba; Argentina
Fil: Garcia, Nestor Horacio. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones en Ciencias de la Salud. Universidad Nacional de Córdoba. Instituto de Investigaciones en Ciencias de la Salud; Argentina. Provincia de Córdoba. Ministerio de Ciencia y Técnica. Centro de Excelencia en Productos y Procesos de Córdoba; Argentina
Materia
ACUTE RESPIRATORY DISTRESS SYNDROME
CORONAVIRUS
COVID-19
HYPOXEMIA
SARS-COV-2
VIRAL PNEUMONIA
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/151020

id CONICETDig_86e232386c64e09b15a8649ccbd9a05c
oai_identifier_str oai:ri.conicet.gov.ar:11336/151020
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Reversal of SARS-CoV2-Induced Hypoxia by Nebulized Sodium Ibuprofenate in a Compassionate Use ProgramSalva, OscarDoreski, Pablo A.Giler, Celia S.Quinodoz, Dario C.Guzmán, Lucia G.Muñoz, Sonia EdithCarrillo, Mariana Norma del VallePorta, Daniela JosefinaAmbasch, GermánCoscia, EstebanTambini Diaz, Jorge L.Bueno, Germán D.Fandi, Jorge O.Maldonado, Miriam A.Peña Chiappero, Leandro E.Fournier, FernandoPérez, Hernán A.Quiroga, Mauro A.Sala Mercado, Javier AgustinMartínez Picco, CarlosBeltrán, Marcelo AlejandroCastillo Argañarás, Luis FernandoRíos, Nicolás MartínezKalayan, Galia I.Beltramo, Dante MiguelGarcia, Nestor HoracioACUTE RESPIRATORY DISTRESS SYNDROMECORONAVIRUSCOVID-19HYPOXEMIASARS-COV-2VIRAL PNEUMONIAhttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Introduction: Sodium ibuprofenate in hypertonic saline (NaIHS) administered directly to the lungs by nebulization and inhalation has antibacterial and anti-inflammatory effects, with the potential to deliver these benefits to hypoxic patients. We describe a compassionate use program that offered this therapy to hospitalized COVID-19 patients. Methods: NaIHS (50 mg ibuprofen, tid) was provided in addition to standard of care (SOC) to hospitalized COVID-19 patients until oxygen saturation levels of > 94% were achieved on ambient air. Patients wore a containment hood to diminish aerosolization. Outcome data from participating patients treated at multiple hospitals in Argentina between April 4 and October 31, 2020, are summarized. Results were compared with a retrospective contemporaneous control (CC) group of hospitalized COVID-19 patients with SOC alone during the same time frame from a subset of participating hospitals from Córdoba and Buenos Aires. Results: The evolution of 383 patients treated with SOC + NaIHS [56 on mechanical ventilation (MV) at baseline] and 195 CC (21 on MV at baseline) are summarized. At baseline, NaIHS-treated patients had basal oxygen saturation of 90.7 ± 0.2% (74.3% were on supplemental oxygen at baseline) and a basal respiratory rate of 22.7 ± 0.3 breath/min. In the CC group, basal oxygen saturation was 92.6 ± 0.4% (52.1% were on oxygen supplementation at baseline) and respiratory rate was 19.3 ± 0.3 breath/min. Despite greater pulmonary compromise at baseline in the NaIHS-treated group, the length of treatment (LOT) was 9.1 ± 0.2 gs with an average length of stay (ALOS) of 11.5 ± 0.3 days, in comparison with an ALOS of 13.3 ± 0.9 days in the CC group. In patients on MV who received NaIHS, the ALOS was lower than in the CC group. In both NaIHS-treated groups, a rapid reversal of deterioration in oxygenation and NEWS2 scores was observed acutely after initiation of NaIHS therapy. No serious adverse events were considered related to ibuprofen therapy. Mortality was lower in both NaIHS groups compared with CC groups. Conclusions: Treatment of COVID-19 pneumonitis with inhalational nebulized NaIHS was associated with rapid improvement in hypoxia and vital signs, with no serious adverse events attributed to therapy. Nebulized NaIHS s worthy of further study in randomized, placebo-controlled trials (ClinicalTrials.gov: NCT04382768).Fil: Salva, Oscar. Clínica Independencia; ArgentinaFil: Doreski, Pablo A.. Fundación Respirar; ArgentinaFil: Giler, Celia S.. Clínica Independencia; ArgentinaFil: Quinodoz, Dario C.. Sanatorio de la Cañada; ArgentinaFil: Guzmán, Lucia G.. Sanatorio de la Cañada; ArgentinaFil: Muñoz, Sonia Edith. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones en Ciencias de la Salud. Universidad Nacional de Córdoba. Instituto de Investigaciones en Ciencias de la Salud; ArgentinaFil: Carrillo, Mariana Norma del Valle. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones en Ciencias de la Salud. Universidad Nacional de Córdoba. Instituto de Investigaciones en Ciencias de la Salud; ArgentinaFil: Porta, Daniela Josefina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones en Ciencias de la Salud. Universidad Nacional de Córdoba. Instituto de Investigaciones en Ciencias de la Salud; ArgentinaFil: Ambasch, Germán. Sanatorio Privado Mayo; ArgentinaFil: Coscia, Esteban. Sanatorio Privado Mayo; ArgentinaFil: Tambini Diaz, Jorge L.. Sanatorio Privado Mayo; ArgentinaFil: Bueno, Germán D.. Sanatorio Privado Mayo; ArgentinaFil: Fandi, Jorge O.. Clínica Independencia; ArgentinaFil: Maldonado, Miriam A.. Sanatorio San Roque; ArgentinaFil: Peña Chiappero, Leandro E.. Sanatori San Roque; ArgentinaFil: Fournier, Fernando. Clínica Francesa; ArgentinaFil: Pérez, Hernán A.. Sanatorio Alive; Argentina. University of Maryland; Estados UnidosFil: Quiroga, Mauro A.. Instituto Modelo de Cardiología; ArgentinaFil: Sala Mercado, Javier Agustin. Instituto Modelo de Cardiología; ArgentinaFil: Martínez Picco, Carlos. Clínica del Sol; ArgentinaFil: Beltrán, Marcelo Alejandro. Hospital Dr. Alberto Duhau; ArgentinaFil: Castillo Argañarás, Luis Fernando. Hospital Dr. Alberto Duhau; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Ríos, Nicolás Martínez. Quimica Luar Srl; ArgentinaFil: Kalayan, Galia I.. Provincia de Córdoba. Ministerio de Ciencia y Técnica. Centro de Excelencia en Productos y Procesos de Córdoba; ArgentinaFil: Beltramo, Dante Miguel. Provincia de Córdoba. Ministerio de Ciencia y Técnica. Centro de Excelencia en Productos y Procesos de Córdoba; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba; ArgentinaFil: Garcia, Nestor Horacio. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones en Ciencias de la Salud. Universidad Nacional de Córdoba. Instituto de Investigaciones en Ciencias de la Salud; Argentina. Provincia de Córdoba. Ministerio de Ciencia y Técnica. Centro de Excelencia en Productos y Procesos de Córdoba; ArgentinaSpringer Nature2021-08info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/151020Salva, Oscar; Doreski, Pablo A.; Giler, Celia S.; Quinodoz, Dario C.; Guzmán, Lucia G.; et al.; Reversal of SARS-CoV2-Induced Hypoxia by Nebulized Sodium Ibuprofenate in a Compassionate Use Program; Springer Nature; Infectious Diseases and Therapy; 10; 4; 8-2021; 2511-25242193-82292193-6382CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://link.springer.com/10.1007/s40121-021-00527-2info:eu-repo/semantics/altIdentifier/doi/10.1007/s40121-021-00527-2info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:15:33Zoai:ri.conicet.gov.ar:11336/151020instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:15:33.904CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Reversal of SARS-CoV2-Induced Hypoxia by Nebulized Sodium Ibuprofenate in a Compassionate Use Program
title Reversal of SARS-CoV2-Induced Hypoxia by Nebulized Sodium Ibuprofenate in a Compassionate Use Program
spellingShingle Reversal of SARS-CoV2-Induced Hypoxia by Nebulized Sodium Ibuprofenate in a Compassionate Use Program
Salva, Oscar
ACUTE RESPIRATORY DISTRESS SYNDROME
CORONAVIRUS
COVID-19
HYPOXEMIA
SARS-COV-2
VIRAL PNEUMONIA
title_short Reversal of SARS-CoV2-Induced Hypoxia by Nebulized Sodium Ibuprofenate in a Compassionate Use Program
title_full Reversal of SARS-CoV2-Induced Hypoxia by Nebulized Sodium Ibuprofenate in a Compassionate Use Program
title_fullStr Reversal of SARS-CoV2-Induced Hypoxia by Nebulized Sodium Ibuprofenate in a Compassionate Use Program
title_full_unstemmed Reversal of SARS-CoV2-Induced Hypoxia by Nebulized Sodium Ibuprofenate in a Compassionate Use Program
title_sort Reversal of SARS-CoV2-Induced Hypoxia by Nebulized Sodium Ibuprofenate in a Compassionate Use Program
dc.creator.none.fl_str_mv Salva, Oscar
Doreski, Pablo A.
Giler, Celia S.
Quinodoz, Dario C.
Guzmán, Lucia G.
Muñoz, Sonia Edith
Carrillo, Mariana Norma del Valle
Porta, Daniela Josefina
Ambasch, Germán
Coscia, Esteban
Tambini Diaz, Jorge L.
Bueno, Germán D.
Fandi, Jorge O.
Maldonado, Miriam A.
Peña Chiappero, Leandro E.
Fournier, Fernando
Pérez, Hernán A.
Quiroga, Mauro A.
Sala Mercado, Javier Agustin
Martínez Picco, Carlos
Beltrán, Marcelo Alejandro
Castillo Argañarás, Luis Fernando
Ríos, Nicolás Martínez
Kalayan, Galia I.
Beltramo, Dante Miguel
Garcia, Nestor Horacio
author Salva, Oscar
author_facet Salva, Oscar
Doreski, Pablo A.
Giler, Celia S.
Quinodoz, Dario C.
Guzmán, Lucia G.
Muñoz, Sonia Edith
Carrillo, Mariana Norma del Valle
Porta, Daniela Josefina
Ambasch, Germán
Coscia, Esteban
Tambini Diaz, Jorge L.
Bueno, Germán D.
Fandi, Jorge O.
Maldonado, Miriam A.
Peña Chiappero, Leandro E.
Fournier, Fernando
Pérez, Hernán A.
Quiroga, Mauro A.
Sala Mercado, Javier Agustin
Martínez Picco, Carlos
Beltrán, Marcelo Alejandro
Castillo Argañarás, Luis Fernando
Ríos, Nicolás Martínez
Kalayan, Galia I.
Beltramo, Dante Miguel
Garcia, Nestor Horacio
author_role author
author2 Doreski, Pablo A.
Giler, Celia S.
Quinodoz, Dario C.
Guzmán, Lucia G.
Muñoz, Sonia Edith
Carrillo, Mariana Norma del Valle
Porta, Daniela Josefina
Ambasch, Germán
Coscia, Esteban
Tambini Diaz, Jorge L.
Bueno, Germán D.
Fandi, Jorge O.
Maldonado, Miriam A.
Peña Chiappero, Leandro E.
Fournier, Fernando
Pérez, Hernán A.
Quiroga, Mauro A.
Sala Mercado, Javier Agustin
Martínez Picco, Carlos
Beltrán, Marcelo Alejandro
Castillo Argañarás, Luis Fernando
Ríos, Nicolás Martínez
Kalayan, Galia I.
Beltramo, Dante Miguel
Garcia, Nestor Horacio
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv ACUTE RESPIRATORY DISTRESS SYNDROME
CORONAVIRUS
COVID-19
HYPOXEMIA
SARS-COV-2
VIRAL PNEUMONIA
topic ACUTE RESPIRATORY DISTRESS SYNDROME
CORONAVIRUS
COVID-19
HYPOXEMIA
SARS-COV-2
VIRAL PNEUMONIA
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Introduction: Sodium ibuprofenate in hypertonic saline (NaIHS) administered directly to the lungs by nebulization and inhalation has antibacterial and anti-inflammatory effects, with the potential to deliver these benefits to hypoxic patients. We describe a compassionate use program that offered this therapy to hospitalized COVID-19 patients. Methods: NaIHS (50 mg ibuprofen, tid) was provided in addition to standard of care (SOC) to hospitalized COVID-19 patients until oxygen saturation levels of > 94% were achieved on ambient air. Patients wore a containment hood to diminish aerosolization. Outcome data from participating patients treated at multiple hospitals in Argentina between April 4 and October 31, 2020, are summarized. Results were compared with a retrospective contemporaneous control (CC) group of hospitalized COVID-19 patients with SOC alone during the same time frame from a subset of participating hospitals from Córdoba and Buenos Aires. Results: The evolution of 383 patients treated with SOC + NaIHS [56 on mechanical ventilation (MV) at baseline] and 195 CC (21 on MV at baseline) are summarized. At baseline, NaIHS-treated patients had basal oxygen saturation of 90.7 ± 0.2% (74.3% were on supplemental oxygen at baseline) and a basal respiratory rate of 22.7 ± 0.3 breath/min. In the CC group, basal oxygen saturation was 92.6 ± 0.4% (52.1% were on oxygen supplementation at baseline) and respiratory rate was 19.3 ± 0.3 breath/min. Despite greater pulmonary compromise at baseline in the NaIHS-treated group, the length of treatment (LOT) was 9.1 ± 0.2 gs with an average length of stay (ALOS) of 11.5 ± 0.3 days, in comparison with an ALOS of 13.3 ± 0.9 days in the CC group. In patients on MV who received NaIHS, the ALOS was lower than in the CC group. In both NaIHS-treated groups, a rapid reversal of deterioration in oxygenation and NEWS2 scores was observed acutely after initiation of NaIHS therapy. No serious adverse events were considered related to ibuprofen therapy. Mortality was lower in both NaIHS groups compared with CC groups. Conclusions: Treatment of COVID-19 pneumonitis with inhalational nebulized NaIHS was associated with rapid improvement in hypoxia and vital signs, with no serious adverse events attributed to therapy. Nebulized NaIHS s worthy of further study in randomized, placebo-controlled trials (ClinicalTrials.gov: NCT04382768).
Fil: Salva, Oscar. Clínica Independencia; Argentina
Fil: Doreski, Pablo A.. Fundación Respirar; Argentina
Fil: Giler, Celia S.. Clínica Independencia; Argentina
Fil: Quinodoz, Dario C.. Sanatorio de la Cañada; Argentina
Fil: Guzmán, Lucia G.. Sanatorio de la Cañada; Argentina
Fil: Muñoz, Sonia Edith. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones en Ciencias de la Salud. Universidad Nacional de Córdoba. Instituto de Investigaciones en Ciencias de la Salud; Argentina
Fil: Carrillo, Mariana Norma del Valle. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones en Ciencias de la Salud. Universidad Nacional de Córdoba. Instituto de Investigaciones en Ciencias de la Salud; Argentina
Fil: Porta, Daniela Josefina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones en Ciencias de la Salud. Universidad Nacional de Córdoba. Instituto de Investigaciones en Ciencias de la Salud; Argentina
Fil: Ambasch, Germán. Sanatorio Privado Mayo; Argentina
Fil: Coscia, Esteban. Sanatorio Privado Mayo; Argentina
Fil: Tambini Diaz, Jorge L.. Sanatorio Privado Mayo; Argentina
Fil: Bueno, Germán D.. Sanatorio Privado Mayo; Argentina
Fil: Fandi, Jorge O.. Clínica Independencia; Argentina
Fil: Maldonado, Miriam A.. Sanatorio San Roque; Argentina
Fil: Peña Chiappero, Leandro E.. Sanatori San Roque; Argentina
Fil: Fournier, Fernando. Clínica Francesa; Argentina
Fil: Pérez, Hernán A.. Sanatorio Alive; Argentina. University of Maryland; Estados Unidos
Fil: Quiroga, Mauro A.. Instituto Modelo de Cardiología; Argentina
Fil: Sala Mercado, Javier Agustin. Instituto Modelo de Cardiología; Argentina
Fil: Martínez Picco, Carlos. Clínica del Sol; Argentina
Fil: Beltrán, Marcelo Alejandro. Hospital Dr. Alberto Duhau; Argentina
Fil: Castillo Argañarás, Luis Fernando. Hospital Dr. Alberto Duhau; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Ríos, Nicolás Martínez. Quimica Luar Srl; Argentina
Fil: Kalayan, Galia I.. Provincia de Córdoba. Ministerio de Ciencia y Técnica. Centro de Excelencia en Productos y Procesos de Córdoba; Argentina
Fil: Beltramo, Dante Miguel. Provincia de Córdoba. Ministerio de Ciencia y Técnica. Centro de Excelencia en Productos y Procesos de Córdoba; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba; Argentina
Fil: Garcia, Nestor Horacio. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones en Ciencias de la Salud. Universidad Nacional de Córdoba. Instituto de Investigaciones en Ciencias de la Salud; Argentina. Provincia de Córdoba. Ministerio de Ciencia y Técnica. Centro de Excelencia en Productos y Procesos de Córdoba; Argentina
description Introduction: Sodium ibuprofenate in hypertonic saline (NaIHS) administered directly to the lungs by nebulization and inhalation has antibacterial and anti-inflammatory effects, with the potential to deliver these benefits to hypoxic patients. We describe a compassionate use program that offered this therapy to hospitalized COVID-19 patients. Methods: NaIHS (50 mg ibuprofen, tid) was provided in addition to standard of care (SOC) to hospitalized COVID-19 patients until oxygen saturation levels of > 94% were achieved on ambient air. Patients wore a containment hood to diminish aerosolization. Outcome data from participating patients treated at multiple hospitals in Argentina between April 4 and October 31, 2020, are summarized. Results were compared with a retrospective contemporaneous control (CC) group of hospitalized COVID-19 patients with SOC alone during the same time frame from a subset of participating hospitals from Córdoba and Buenos Aires. Results: The evolution of 383 patients treated with SOC + NaIHS [56 on mechanical ventilation (MV) at baseline] and 195 CC (21 on MV at baseline) are summarized. At baseline, NaIHS-treated patients had basal oxygen saturation of 90.7 ± 0.2% (74.3% were on supplemental oxygen at baseline) and a basal respiratory rate of 22.7 ± 0.3 breath/min. In the CC group, basal oxygen saturation was 92.6 ± 0.4% (52.1% were on oxygen supplementation at baseline) and respiratory rate was 19.3 ± 0.3 breath/min. Despite greater pulmonary compromise at baseline in the NaIHS-treated group, the length of treatment (LOT) was 9.1 ± 0.2 gs with an average length of stay (ALOS) of 11.5 ± 0.3 days, in comparison with an ALOS of 13.3 ± 0.9 days in the CC group. In patients on MV who received NaIHS, the ALOS was lower than in the CC group. In both NaIHS-treated groups, a rapid reversal of deterioration in oxygenation and NEWS2 scores was observed acutely after initiation of NaIHS therapy. No serious adverse events were considered related to ibuprofen therapy. Mortality was lower in both NaIHS groups compared with CC groups. Conclusions: Treatment of COVID-19 pneumonitis with inhalational nebulized NaIHS was associated with rapid improvement in hypoxia and vital signs, with no serious adverse events attributed to therapy. Nebulized NaIHS s worthy of further study in randomized, placebo-controlled trials (ClinicalTrials.gov: NCT04382768).
publishDate 2021
dc.date.none.fl_str_mv 2021-08
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/151020
Salva, Oscar; Doreski, Pablo A.; Giler, Celia S.; Quinodoz, Dario C.; Guzmán, Lucia G.; et al.; Reversal of SARS-CoV2-Induced Hypoxia by Nebulized Sodium Ibuprofenate in a Compassionate Use Program; Springer Nature; Infectious Diseases and Therapy; 10; 4; 8-2021; 2511-2524
2193-8229
2193-6382
CONICET Digital
CONICET
url http://hdl.handle.net/11336/151020
identifier_str_mv Salva, Oscar; Doreski, Pablo A.; Giler, Celia S.; Quinodoz, Dario C.; Guzmán, Lucia G.; et al.; Reversal of SARS-CoV2-Induced Hypoxia by Nebulized Sodium Ibuprofenate in a Compassionate Use Program; Springer Nature; Infectious Diseases and Therapy; 10; 4; 8-2021; 2511-2524
2193-8229
2193-6382
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://link.springer.com/10.1007/s40121-021-00527-2
info:eu-repo/semantics/altIdentifier/doi/10.1007/s40121-021-00527-2
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Springer Nature
publisher.none.fl_str_mv Springer Nature
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844614092286853120
score 13.070432